Insider

Gilead Sciences, Inc.

GILD Health Care · 2 analyses

Gilead Sciences reported $8.3B in revenue (+6.8% YoY), compared with a +7.2% median across covered Health Care peers. 11 insider sales recorded. Its latest periodic filing added 29 new risk factors. Next scheduled event: Dividend on December 30, 2026.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Deals & ownership

Керівники Gilead Sciences повідомили про низку операцій з акціями

Протягом періоду з 9 по 16 листопада 2026 року керівники та директори Gilead Sciences, Inc. здійснили низку операцій з акціями та подали нові повідомлення про плани майбутніх продажів. Ці транзакції та наміри задокументовані у регуляторних звітах компанії.

· Gilead Sciences, Inc.
Deals & ownership

Gilead Sciences: executives sold shares under predetermined plans

On October 15, 2026, two Gilead Sciences executives, Chief Financial Officer Andrew Dickinson and Chief Communications Officer Johanna Mercier, sold company shares. Each sold 3,000 shares at $156.22 per share, totaling approximately $468,660 for each transaction. Both operations were conducted under pre-approved trading plans, which set a specific sale schedule.

· Gilead Sciences, Inc.

Upcoming events

As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →

Company history

October 2026

GILEAD SCIENCES, INC.: 9 recorded developments from 9 official sources in 2026-10.

  • 2026-09-15: Units to be sold: 3000; aggregate market value: 435870 USD; units outstanding: 1239955155 Source
  • 2026-09-15: Units to be sold: 3000; aggregate market value: 432646.2 USD; units outstanding: 1239955155 Source
  • 2026-09-16: Summary: S (open market or private sale): 1 transaction(s) on 2026-09-15, 3,000 disposed, total value 435,870 USD at a weighted average price of 145.29 USD; owned after the last one: 164,096 Source
  • 2026-09-16: Summary: S (open market or private sale): 3 transaction(s) on 2026-09-15, 3,000 disposed, total value 432,646.24 USD at a weighted average price of 144.2154 USD; owned after the last one: 116,684 Source
  • 2026-10-02: Summary: S (open market or private sale): 2 transaction(s) on 2026-10-01, 15,000 disposed, total value 2,218,507.5 USD at a weighted average price of 147.9005 USD; owned after the last one: 566,683 Source
  • 2026-10-15: Units to be sold: 3000; aggregate market value: 468660 USD; units outstanding: 1239955155 Source
  • 2026-10-15: Units to be sold: 3000; aggregate market value: 468660 USD; units outstanding: 1239955155 Source
  • 2026-10-16: Summary: S (open market or private sale): 1 transaction(s) on 2026-10-15, 3,000 disposed, total value 468,660 USD at a weighted average price of 156.22 USD; owned after the last one: 161,096 Source
  • 2026-10-16: Summary: S (open market or private sale): 1 transaction(s) on 2026-10-15, 3,000 disposed, total value 468,660 USD at a weighted average price of 156.22 USD; owned after the last one: 113,684 Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 30, 2026. SEC

LatestEarlierChange
Revenue quarter$8.3B$7.8B+6.8%
Operating income quarter$3.5B$3.3B+4.1%
Net income quarter$2.4B$3.1B-20.4%
Diluted EPS quarter$1.94$2.43-20.2%
Dividends per share quarter$0.82$0.79+3.8%
Operating cash flow year to date$11.2B$6.7B+66.6%
Long-term debt balance$23.8B$22.1B+7.6%

Next results expected around January 29, 2027 (estimate: the quarter ending about December 30, 2026 plus the 30 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Gilead Sciences, Inc. GILD$8.3B+6.8%41.7%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Changes in risk factors

The 10-Q filed October 30, 2026 compared with the 10-Q filed August 6, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (29)

  • | | (3) | | | — | | | (12) | | | — | | | (358) | | | — | | | (370)
  • | | — | | | — | | | — | | | — | | | (1,029) | | | — | | | (1,029)
  • Balance as of September 30, 2026 | | 1,241 | | | $ | 1 | | | $ | 9,841 | | | $ | 89 | | | $ | 3,107 | | | $ | (84) | | | $ | 12,955

Dropped (27)

  • Balance as of March 31, 2026 | | 1,242 | | | $ | 1 | | | $ | 9,305 | | | $ | 78 | | | $ | 14,131 | | | $ | (84) | | | $ | 23,431
  • | | (3) | | | — | | | (12) | | | — | | | (343) | | | — | | | (355)
  • | | — | | | — | | | — | | | — | | | (1,031) | | | — | | | (1,031)

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 16, 2026Johanna MercierSale 10b5-1 plan notice filed28,000$170.55$4,775,527SEC
November 16, 2026Andrew D DickinsonSale 10b5-1 plan notice filed3,000$171.47$514,410SEC
November 12, 2026Kelly A. KramerSale 10b5-1 plan notice filed10,376$169.76$1,761,437SEC
November 6, 2026Wettan Keeley M CainSale 10b5-1 plan notice filed3,399$164.11$557,810SEC
November 5, 2026Daniel Patrick O'DaySale 10b5-1 plan112,429$175.16$19,693,439SEC
November 4, 2026Daniel O'DayPlanned sale 10b5-1 plan112,429—$18,828,485SEC
November 2, 2026Daniel Patrick O'DaySale 10b5-1 plan30,881$172.57$5,329,178SEC
October 30, 2026Daniel O'DayPlanned sale 10b5-1 plan45,881—$7,598,352SEC
October 15, 2026Andrew D DickinsonSale 10b5-1 plan notice filed3,000$156.22$468,660SEC
October 15, 2026Johanna MercierSale 10b5-1 plan notice filed3,000$156.22$468,660SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock125,246,865$18,668,045,217+2.8%Q3 2026
State Street60,954,967$9,085,337,831-0.4%Q3 2026
Fidelity (FMR)58,265,696$8,684,501,953-12.9%Q3 2026
Geode Capital Management30,190,640$4,485,711,723+0.4%Q3 2026
Capital Research Global Investors23,980,766$3,574,341,919+23.7%Q3 2026
Norges Bank (Norway's sovereign fund)21,965,555$2,775,128,219—Q2 2026
Wellington Management12,224,488$1,822,059,937-3.7%Q3 2026
Renaissance Technologies2,054,876$306,279,268-7.3%Q3 2026
D. E. Shaw & Co.1,909,369$284,591,449-16.8%Q3 2026
Citadel Advisors1,730,709$257,962,177-50.3%Q3 2026
Millennium Management1,628,685$242,755,499+11.6%Q3 2026
Two Sigma Investments517,066$77,068,687+26.4%Q3 2026
Bridgewater Associates321,419$47,907,502+10.5%Q3 2026
T. Rowe Price27,664,121$4,123,338-7.8%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.